JP2022506839A5 - - Google Patents

Info

Publication number
JP2022506839A5
JP2022506839A5 JP2021524449A JP2021524449A JP2022506839A5 JP 2022506839 A5 JP2022506839 A5 JP 2022506839A5 JP 2021524449 A JP2021524449 A JP 2021524449A JP 2021524449 A JP2021524449 A JP 2021524449A JP 2022506839 A5 JP2022506839 A5 JP 2022506839A5
Authority
JP
Japan
Prior art keywords
vaccine composition
mrna
cancer vaccine
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060208 external-priority patent/WO2020097291A1/en
Publication of JP2022506839A publication Critical patent/JP2022506839A/ja
Publication of JP2022506839A5 publication Critical patent/JP2022506839A5/ja
Priority to JP2025016804A priority Critical patent/JP2025071108A/ja
Pending legal-status Critical Current

Links

JP2021524449A 2018-11-07 2019-11-07 Rnaがんワクチン Pending JP2022506839A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025016804A JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862757057P 2018-11-07 2018-11-07
US62/757,057 2018-11-07
US201962813900P 2019-03-05 2019-03-05
US62/813,900 2019-03-05
US201962855335P 2019-05-31 2019-05-31
US62/855,335 2019-05-31
PCT/US2019/060208 WO2020097291A1 (en) 2018-11-07 2019-11-07 Rna cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025016804A Division JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Publications (2)

Publication Number Publication Date
JP2022506839A JP2022506839A (ja) 2022-01-17
JP2022506839A5 true JP2022506839A5 (https=) 2022-11-15

Family

ID=70612163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524449A Pending JP2022506839A (ja) 2018-11-07 2019-11-07 Rnaがんワクチン
JP2025016804A Pending JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025016804A Pending JP2025071108A (ja) 2018-11-07 2025-02-04 Rnaがんワクチン

Country Status (6)

Country Link
US (1) US20220125899A1 (https=)
EP (1) EP3876947A4 (https=)
JP (2) JP2022506839A (https=)
CA (1) CA3118947A1 (https=)
MA (1) MA54192A (https=)
WO (1) WO2020097291A1 (https=)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
AU2018219862B2 (en) * 2017-02-07 2020-09-17 Nant Holding IP, LLC Maximizing T-cell memory and compositions and methods therefor
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MA49914A (fr) 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
JP2023546133A (ja) * 2020-10-14 2023-11-01 アールエヌエーイミューン、インコーポレイテッド 汎RAS mRNAがんワクチン
WO2022125511A1 (en) * 2020-12-07 2022-06-16 Iogenetics, Llc Administration of anti-tumor vaccines
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
CA3211083A1 (en) * 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
WO2022197599A1 (en) * 2021-03-18 2022-09-22 Ne1 Inc. Cancer vaccine and method of use thereof
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4147712A1 (en) * 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
EP4147713A1 (en) * 2021-09-13 2023-03-15 OncoDNA A rna vaccine comprising an rna pool generated from a double-stranded dna pool
CA3230564A1 (en) 2021-09-13 2023-03-16 Jean-Pol DETIFFE Method to generate personalized neoantigens of a tumor of a patient
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
JPWO2024038857A1 (https=) 2022-08-16 2024-02-22
EP4364752A1 (en) 2022-11-07 2024-05-08 OncoDNA Improved vaccine
EP4648793A1 (en) * 2023-01-11 2025-11-19 ModernaTX, Inc. Personalized cancer vaccines
CN121311226A (zh) 2023-05-17 2026-01-09 特沙诺有限公司 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途
WO2025087266A1 (en) 2023-10-23 2025-05-01 Abogen Biosciences (Shanghai) Co., Ltd. Immunomodulatory mrna cassettes, and uses thereof
WO2025117816A1 (en) * 2023-12-01 2025-06-05 Recode Therapeutics, Inc. Lipid nanoparticle compositions and uses thereof
CN121064279A (zh) * 2024-06-04 2025-12-05 复旦大学附属中山医院 一种抗肝癌hla-a*11型疫苗及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
PL3892295T3 (pl) * 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
EP3417874B1 (en) * 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
EP3292873B1 (en) * 2013-02-22 2019-05-01 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
EP2983702A2 (en) * 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2016184822A1 (en) * 2015-05-15 2016-11-24 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
MA42543A (fr) * 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
AU2016341309A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
US11464847B2 (en) * 2016-12-23 2022-10-11 Curevac Ag Lassa virus vaccine
CN109152830B (zh) * 2017-01-27 2023-11-03 卫理公会医院 用于免疫疗法的核/壳结构平台
US20190351040A1 (en) * 2017-02-01 2019-11-21 Modernatx, Inc. Rna cancer vaccines
JP2020514370A (ja) * 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤

Similar Documents

Publication Publication Date Title
JP2022506839A5 (https=)
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
JP2023118967A (ja) 腫瘍変異負荷
JP2019513373A5 (https=)
JP2018518454A5 (https=)
JP2018526323A5 (https=)
JP2021513541A5 (https=)
KR20180022968A (ko) 난소암 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
TW201625270A (zh) 用於治療贅瘤形成的治療組合及方法
TW201731527A (zh) 使用抗pd-1抗體與抗clta-4抗體之組合以治療肺癌
JP2013505223A (ja) EpCAMxCD3二重特異性抗体を投与するための投与計画
JP7809635B2 (ja) Lag-3アンタゴニスト治療のための定量的空間プロファイリング
Pan et al. Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
JP2022537411A (ja) 抗tim-3抗体
CN111278992A (zh) 用抗egfr抗体治疗癌症的组合物和方法
JP2023502876A5 (https=)
CN118001389A (zh) 膀胱癌的抗pd-l1抗体治疗
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
US20250179176A1 (en) Anti-tigit antibodies and uses of the same
CN115485298A (zh) 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合
JP2024536383A5 (https=)
TWI865617B (zh) 抗原結合蛋白
JP2023548590A (ja) 小細胞肺がんの分類と治療のための方法およびシステム
WO2018057858A1 (en) Determinants of cancer response to immunotherapy
WO2019207030A1 (en) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer